Can NAD+/NR supplementation help with chronic inflammation or autoimmune symptoms?

Short answer, , but they are not yet proven medical treatments for autoimmune diseases. This is, somewhat surprisingly, one of the better-supported areas of NAD+ research in humans — better supported than the weight, energy, or anti-aging claims that get more marketing attention. But the evidence is early and should be read carefully.

The clearest human data comes from a psoriasis trial. Researchers ran a randomized, placebo-controlled study in people with mild-to-moderate psoriasis, giving 500 mg of oral NR twice daily (1,000 mg/day total) or matching placebo for four weeks. NR reduced Th17 immune responsiveness — Th17 being a T-cell population central to psoriasis and several other autoimmune conditions — and RNA sequencing of CD4+ T cells identified activation of the SLIT-ROBO signaling pathway as a mechanism. This is genuinely notable: it's a randomized human trial in an autoimmune condition showing a measurable immunological effect, not just a biomarker shift.

Inflammatory cytokines drop in healthy older adults too. A placebo-controlled, double-blind, crossover trial gave 12 men aged 70–80 one gram of NR daily for 21 days. Alongside raising the skeletal muscle NAD+ metabolome, NR depressed circulating inflammatory cytokine levels. Researchers measured a broad panel including IL-6, TNF-α, IFN-γ, IL-2, IL-8, MCP-1, and hsCRP.

The mechanism is coherent. Genetic mitochondrial defects, degenerative conditions, autoimmune and inflammatory diseases, and aging itself are all associated with reduced NAD+ levels. And nicotinamide has been shown to suppress CD4+ T-cell activation in laboratory work — impairing proliferation, reducing activation markers, and lowering production of IL-2, IFN-γ, and IL-17. This connects back to CD38: inflammation raises CD38, CD38 consumes NAD+, and low NAD+ appears to further impair immune regulation. Intervening in that loop is a reasonable therapeutic idea.

The honest limitations. The psoriasis trial ran four weeks; the cytokine trial involved twelve people over three weeks. These are small, short studies establishing biological plausibility — not evidence that NR treats autoimmune disease or should replace anything. No NAD+ precursor is approved for any autoimmune or inflammatory condition.

A genuinely important caution for autoimmune conditions: NAD+ and CD38 are deeply involved in normal immune function, and modulating immune responsiveness is not automatically desirable in every context. If you have an autoimmune condition, you're likely on medication that modulates your immune system already, and adding something that measurably affects T-cell behavior is not a decision to make alone.

If you have any chronic condition — autoimmune disease, liver or kidney disease, diabetes — or take prescription medication, please discuss NAD+ precursors with your doctor before starting. The research here is promising, but "promising early research" and "appropriate for your specific situation" are different questions, and only someone who knows your full history can answer the second one.

Sources for this question:

• JCI Insight, "NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis" — https://pmc.ncbi.nlm.nih.gov/articles/PMC13313537/
• Cell Reports, "Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures" (Elhassan et al., 2019) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702140/
• PubMed record for Elhassan et al. — https://pubmed.ncbi.nlm.nih.gov/31412242/
• PMC, "Nicotinamide Inhibits CD4+ T-Cell Activation and Function" — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025565/
• ChromaDex/BusinessWire announcement of the psoriasis inflammation study — https://www.businesswire.com/news/home/20231002427548/en/